Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Chronic Myeloid Leukemia (Prescribing Decisions and Payer Landscape in a Crowded and Changing U.S. Market) | Physician & Payer Forum | US | 2014
Despite the comparatively low incidence of chronic myeloid leukemia (CML) in the United States, patient management requires extended durations of therapy, which in turn translates into a…
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | Decision Base | US/EU | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | DecisionBase | US/EU5/Asia Pacific | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
Hepatitis C Virus (Primary Care Physicians in an Interferon-Free World: How Will the Availability of Safer and More Effective Oral Therapies Impact the Role of PCPs in Treating HCV Patients?) | Physician & Payer Forum | US | 2014
The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based…
U.S. Prescriber and Payer Receptivity to Emerging Agents for Treatment-Resistant Depression Amid a Crowded and Increasingly Genericized Market | Physician & Payer Forum | US | 2014
Major depressive disorder (MDD) continues to be a highly prevalent psychiatric disorder. Over 5 million drug-treated MDD patients in the United States fail to respond adequately to treatment with…
Renal Anemia in Chronic Kidney Disease Non-Dialysis | Chart Trends | China | 2014
Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define…
Patient Access to High-Cost Therapies for CML in LATAM: How Do Payers and Physicians Shape This Crowded and Changing Market? | Physician & Payer Forum | Brazil and Mexico | 2014
The treatment armamentarium for chronic myelogenous leukemia (CML) in Brazil and Mexico includes all three currently marketed tyrosine kinase inhibitors (TKIs): Glivec (imatinib,Novartis) for newly…
Marketing to U.S. Digital Physicians: Engaging Physicians Across Screens and Platforms
Changes in U.S. policy have accelerated the implementation and use of electronic health records (EHRs) in the practice, disrupting physician workflow and decision making. In the meanwhile, reliance…
